Stocks in play: Medexus Pharmaceuticals

And medac, a strategic partner of Medexus, are pleased to announce that medac has resubmitted its New Drug Application for Treosulfan (NDA) with the U.S. Food and Drug Administration (FDA). The NDA requests approval of Treosulfan in combination with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation (allo-HSCT). The resubmission includes additional clinical data and statistical analysis relating to the previously-completed phase 3 clinical trial of Treosulfan as well as an update of the integrated summary of safety, which the FDA had requested in their July 2021 Complete Response Letter to medac. Medexus Pharmaceuticals shares T.MDP are trading up $0.07 at $3.06.

Read:

• New Developments in Solid Tumor Therapeutics Continue to Give Hope to Patients

• Surging Dogecoin (DOGE) Acceptance and Value Has the Backing of Multiple Major Tech CEOs

• Supply Shocks Causing More Innovation from Food Companies in Face of Conflict and Climate Change

• CEOs and Corporations Pledging Millions in Support for Ukrainian Humanitarian Efforts

• Dogecoin Acceptance on the Rise as More Corporations and Countries Embrace the DOGE